Skip to main content

Table 1 Molecular and clinical characteristics of patients with essential thrombocythemia (ET)

From: A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients

VariablesCALR mutation (n = 22)JAK2 V617F mutation (n = 28)Triple Negative (n = 14)p-value
Males (%)15 (68.2)12 (42.9)6 (42.9)0.395
Age,
Median (Range)
35 (28–73)57.5 (34.0–85.0)35 (18–75)0.001**
Risk Group:
 Low (%)151420.043*
 High (%)71412 
Haemoglobin (g/dL),
Median (Range)
10.2 (9.2–11.1)12.3 (10.5–15.1)12.8 (11.7–16.8)0.641
TLC ×109/L,
Median (Range)
9.3 (5.11–16.7)9.5 (4.7–147)11.2 (2.3147)0.061
Platelet ×109/L,
Median (Range)
1003.0 (462–2305)928.5 (92–1883)1064.5 (382–1841)0.373
Reticulin Fibrosis
MF 012 (54.5)20 (71.4)10 (71.4) 
MF 17 (318)8 (28.6)4 (28.6)0.052
MF 23 (13.6)00 
Constitutional symptoms (%)13 (59.1)13 (46.4)4 (28.6) 
Thromboembolic events (%)3 (13.6)4 (14.3)2(14.3)0.033*
  1. **highly significant, *significant